Head-to-head evidence
Dapagliflozin vs THR-1442
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Dapagliflozin · Farxiga / Forxiga
Marketed by AstraZeneca
NCT00528372 · Phase 3 · completed
The study was randomized, double-blind, placebo-controlled, and included 1,067 enrolled participants, with 558 receiving short-term treatment; its primary HbA1c endpoint is an accepted disease-defining measure for type 2 diabetes. Results were mixed across the primary dose comparisons: 5 mg and 10 mg morning doses significantly outperformed placebo, while 2.5 mg did not, and the exploratory high-baseline-HbA1c group lacked a comparator.
Next expected readout: October 2026 · NCT07033585 (registry estimate)
THR-1442
Developed by Newsoara Biopharma
NCT05369078 · Phase 1 · status unknown
This was a small, non-randomized, unblinded study in healthy volunteers with no placebo or comparator arm, designed only to characterize safety and drug levels. Results have not yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapagliflozin's landscape · THR-1442's landscape